Sign inJoin waitlistJoin the waitlist

DB

Deepak Bhamidipati

Physician · Verdi Oncology Tennessee PC

Credentials: · · · · · ·

History

Verdi Oncology Tennessee PC
2025–Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2021–2024
Internal Medicine
University of Texas Health Science Center at Houston
2018–2021
Doctor of Medicine
2014–2018
Hematology and Medical Oncology Fellow
University of Texas M D Anderson Cancer Center

Research

PARP inhibitors: enhancing efficacy through rational combinations
Review · British Journal of Cancer · 2023 · First of 4 authors · 145 citations
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Review · Trends in cancer · 2023 · First of 2 authors · 40 citations
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Journal of Neuro-Oncology · 2018 · 34 citations

Vivek Subbiah
7 papers
Joshua Palmer
6 papers · 1 as a resident
Michael Overman
6 papers
WS
Wenyin Shi
6 papers
Scott Kopetz
5 papers
Daniel Fox
4 papers · 3 as a fellow
Jon Glass
4 papers
Kanwal Raghav
4 papers
Lyndon Kim
4 papers
Maria Werner-Wasik
4 papers
Van Morris
4 papers
David Andrews
3 papers

Clinical trials

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Study chair · Recruiting · Phase 1
PMV Pharmaceuticals, Inc
2026–2028
A Study of TAK-505 in Adults With Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Takeda
2026–2030
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
GlaxoSmithKline
2025–2028
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Site PI · Recruiting · Phase 1
Accent Therapeutics
2025–2027